Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine

Daniela Frasca, Alain Diaz, Maria Romero, Nicholas V. Mendez, Ana Marie Landin, John Ryan, Bonnie B Blomberg

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We evaluated immune response to the seasonal influenza vaccine in young and elderly patients with type 2 diabetes (T2D). Immune measures included the in vivo serum response to the vaccine by hemagglutination inhibition (HAI) and ELISA in 22 patients (14 young, 8 elderly) and 65 healthy age-matched controls (37 young, 28 elderly). B cell-specific biomarkers of optimal vaccine response were measured ex vivo by switched memory B cells and plasmablasts and in vitro by activation-induced cytidine deaminase (AID) in stimulated cells. Markers of systemic and B cell-intrinsic inflammation were also measured. Results show that in vivo responses, as well as B cell-specific markers identified above, decrease by age in healthy individuals but not in T2D patients. This occurred despite high levels of B cell-intrinsic inflammation (TNF-α) in T2D patients, which was surprising as we had previously demonstrated this negatively impacts B cell function. These results altogether suggest that valid protection against influenza can be achieved in T2D patients and proposed mechanisms are discussed.

Original languageEnglish
Pages (from-to)3603-3610
Number of pages8
JournalVaccine
Volume31
Issue number35
DOIs
StatePublished - Aug 2 2013

Fingerprint

Influenza Vaccines
noninsulin-dependent diabetes mellitus
influenza
Type 2 Diabetes Mellitus
B-lymphocytes
B-Lymphocytes
vaccines
Vaccines
inflammation
Inflammation
Hemagglutination
hemagglutination
Human Influenza
biomarkers
Biomarkers
Enzyme-Linked Immunosorbent Assay
immune response
enzyme-linked immunosorbent assay
Serum
cells

Keywords

  • Antibody responses
  • Inflammation
  • Influenza vaccine
  • Type 2 diabetes

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. / Frasca, Daniela; Diaz, Alain; Romero, Maria; Mendez, Nicholas V.; Landin, Ana Marie; Ryan, John; Blomberg, Bonnie B.

In: Vaccine, Vol. 31, No. 35, 02.08.2013, p. 3603-3610.

Research output: Contribution to journalArticle

Frasca, Daniela ; Diaz, Alain ; Romero, Maria ; Mendez, Nicholas V. ; Landin, Ana Marie ; Ryan, John ; Blomberg, Bonnie B. / Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. In: Vaccine. 2013 ; Vol. 31, No. 35. pp. 3603-3610.
@article{9ac30dd881a149f083073f6d1f3208e7,
title = "Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine",
abstract = "We evaluated immune response to the seasonal influenza vaccine in young and elderly patients with type 2 diabetes (T2D). Immune measures included the in vivo serum response to the vaccine by hemagglutination inhibition (HAI) and ELISA in 22 patients (14 young, 8 elderly) and 65 healthy age-matched controls (37 young, 28 elderly). B cell-specific biomarkers of optimal vaccine response were measured ex vivo by switched memory B cells and plasmablasts and in vitro by activation-induced cytidine deaminase (AID) in stimulated cells. Markers of systemic and B cell-intrinsic inflammation were also measured. Results show that in vivo responses, as well as B cell-specific markers identified above, decrease by age in healthy individuals but not in T2D patients. This occurred despite high levels of B cell-intrinsic inflammation (TNF-α) in T2D patients, which was surprising as we had previously demonstrated this negatively impacts B cell function. These results altogether suggest that valid protection against influenza can be achieved in T2D patients and proposed mechanisms are discussed.",
keywords = "Antibody responses, Inflammation, Influenza vaccine, Type 2 diabetes",
author = "Daniela Frasca and Alain Diaz and Maria Romero and Mendez, {Nicholas V.} and Landin, {Ana Marie} and John Ryan and Blomberg, {Bonnie B}",
year = "2013",
month = "8",
day = "2",
doi = "10.1016/j.vaccine.2013.05.003",
language = "English",
volume = "31",
pages = "3603--3610",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "35",

}

TY - JOUR

T1 - Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine

AU - Frasca, Daniela

AU - Diaz, Alain

AU - Romero, Maria

AU - Mendez, Nicholas V.

AU - Landin, Ana Marie

AU - Ryan, John

AU - Blomberg, Bonnie B

PY - 2013/8/2

Y1 - 2013/8/2

N2 - We evaluated immune response to the seasonal influenza vaccine in young and elderly patients with type 2 diabetes (T2D). Immune measures included the in vivo serum response to the vaccine by hemagglutination inhibition (HAI) and ELISA in 22 patients (14 young, 8 elderly) and 65 healthy age-matched controls (37 young, 28 elderly). B cell-specific biomarkers of optimal vaccine response were measured ex vivo by switched memory B cells and plasmablasts and in vitro by activation-induced cytidine deaminase (AID) in stimulated cells. Markers of systemic and B cell-intrinsic inflammation were also measured. Results show that in vivo responses, as well as B cell-specific markers identified above, decrease by age in healthy individuals but not in T2D patients. This occurred despite high levels of B cell-intrinsic inflammation (TNF-α) in T2D patients, which was surprising as we had previously demonstrated this negatively impacts B cell function. These results altogether suggest that valid protection against influenza can be achieved in T2D patients and proposed mechanisms are discussed.

AB - We evaluated immune response to the seasonal influenza vaccine in young and elderly patients with type 2 diabetes (T2D). Immune measures included the in vivo serum response to the vaccine by hemagglutination inhibition (HAI) and ELISA in 22 patients (14 young, 8 elderly) and 65 healthy age-matched controls (37 young, 28 elderly). B cell-specific biomarkers of optimal vaccine response were measured ex vivo by switched memory B cells and plasmablasts and in vitro by activation-induced cytidine deaminase (AID) in stimulated cells. Markers of systemic and B cell-intrinsic inflammation were also measured. Results show that in vivo responses, as well as B cell-specific markers identified above, decrease by age in healthy individuals but not in T2D patients. This occurred despite high levels of B cell-intrinsic inflammation (TNF-α) in T2D patients, which was surprising as we had previously demonstrated this negatively impacts B cell function. These results altogether suggest that valid protection against influenza can be achieved in T2D patients and proposed mechanisms are discussed.

KW - Antibody responses

KW - Inflammation

KW - Influenza vaccine

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84880709954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880709954&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.003

DO - 10.1016/j.vaccine.2013.05.003

M3 - Article

VL - 31

SP - 3603

EP - 3610

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 35

ER -